Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hermans

Showing results (81-90 of 364) with videos related to

Pageof 37
Sort By:
Diabetes & Metabolism|November 10, 2009
Erectile dysfunction, microangiopathy and UKPDS risk in type 2 diabetesMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
BMC Endocrine Disorders|August 7, 2019
Distinction of cardiometabolic profiles among people ≥75 years with type 2 diabetes: a latent profile analysisAntoine Christiaens, Michel P Hermans, Benoit Boland, et al.
Acta Clinica Belgica|November 11, 1999
Insulin lispro (Humalog), a novel fast-acting insulin analogue: guidelines for its practical useF R Nobels, M P Hermans, I De Leeuw
Acta Gastro-Enterologica Belgica|March 7, 2003
Primary neutrophil-rich, CD30-positive anaplastic large cell lymphoma of the stomach: case report and review of the literatureM Kahaleh, P Hermans, M Buset, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 18, 1976
[Deep burns of the hands]F G Bouman, J J Bloem, R P Hermans
Journal of Diabetes and Its Complications|September 4, 2019
Increased CRP: An extended biomarker of microvascular risk in men with type 2 diabetesMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
Cardiovascular Diabetology|March 12, 2014
Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipidsMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
Acta Clinica Belgica|January 24, 2013
Predictive factors associated with primary failure to exenatide and non goal attainment in patients with type 2 diabetesV Preumont, M P Hermans, M Bergman, et al.
Current Atherosclerosis Reports|July 17, 2020
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?Jean-Charles Fruchart, Michel P Hermans, Jamila Fruchart-Najib
Journal of Clinical & Translational Endocrinology|July 14, 2023
Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetesFabian Lurquin, Sophie Gohy, Michel P Hermans, et al.
Pageof 37

Showing results (81-90 of 364) with videos related to

Sort By:
Pageof 37
Diabetes & Metabolism|November 10, 2009
Erectile dysfunction, microangiopathy and UKPDS risk in type 2 diabetesMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
BMC Endocrine Disorders|August 7, 2019
Distinction of cardiometabolic profiles among people ≥75 years with type 2 diabetes: a latent profile analysisAntoine Christiaens, Michel P Hermans, Benoit Boland, et al.
Acta Clinica Belgica|November 11, 1999
Insulin lispro (Humalog), a novel fast-acting insulin analogue: guidelines for its practical useF R Nobels, M P Hermans, I De Leeuw
Acta Gastro-Enterologica Belgica|March 7, 2003
Primary neutrophil-rich, CD30-positive anaplastic large cell lymphoma of the stomach: case report and review of the literatureM Kahaleh, P Hermans, M Buset, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 18, 1976
[Deep burns of the hands]F G Bouman, J J Bloem, R P Hermans
Journal of Diabetes and Its Complications|September 4, 2019
Increased CRP: An extended biomarker of microvascular risk in men with type 2 diabetesMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
Cardiovascular Diabetology|March 12, 2014
Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipidsMichel P Hermans, Sylvie A Ahn, Michel F Rousseau
Acta Clinica Belgica|January 24, 2013
Predictive factors associated with primary failure to exenatide and non goal attainment in patients with type 2 diabetesV Preumont, M P Hermans, M Bergman, et al.
Current Atherosclerosis Reports|July 17, 2020
Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?Jean-Charles Fruchart, Michel P Hermans, Jamila Fruchart-Najib
Journal of Clinical & Translational Endocrinology|July 14, 2023
Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetesFabian Lurquin, Sophie Gohy, Michel P Hermans, et al.
Pageof 37